Medtronic confirms Corventis takeover; Pulsar Vascular receives IDE;

@FierceMedDev: ICYMI yesterday: Devicemakers like $MDT, $ABT and $JNJ hold a total of $95 billion offshore--and that's just the tip of the iceberg. Article | Follow @FierceMedDev

@VarunSaxena2: This just in: $MDT will not pursue shareholder complaints against officers, board of directors over Infuse marketing. Filings | Follow @VarunSaxena2

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: "Hackathons" bring together med tech minds to brainstorm innovative solutions to unmet needs in developing countries. Story from Wired | Follow @EmilyWFierce

> Medtronic ($MDT) confirms media reports that it is buying Corventis, maker of a wireless patch that monitors the heart. Story

> The Asian Harmonization Working Party released a white paper on regulating medical device software. Story

> Pulsar Vascular received FDA IDE approval for the PulseRider aneurysm neck reconstruction device. Release

> Cohera Medical announced that the FDA advisory panel hearing for its TissuGlu surgical adhesive will take place on Aug. 1. Release

Biotech News

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Editor's corner | Follow @FierceBiotech

@JohnCFierce: Still trending: Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide. Article | Follow @JohnCFierce

@DamianFierce: Theme in $AGN's new slides: $VRX's big rush to do a deal is wild suspicious. More | Follow @DamianFierce

@EmilyMFierce: Compound could delay onset of Type 2 diabetes. FierceBiotech Research story | Follow @EmilyMFierce

> Allergan says no to $53B as Valeant gets hostile. Item

> Receptos shares spike as oral drug reduces brain lesions in PhII MS trial. More

> Dutch biotech arGEN-X plots an IPO as it pads its list of partners. Report

> Analysis: Idenix bidding was competitive, driving up the deal value for an eager Merck. Article

Pharma News

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion. | Follow @TracyStaton

@EricPFierce: New FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. More | Follow @EricPFierce

@CarlyHFierce: Allergan spurns Valeant again, but shareholders may have other ideas. Article | Follow @CarlyHFierce

@JustinHFierce: After 7mil US pig deaths from PEDv, Tokyo announces outbreak guidelines on concerns of health-conscious Chinese. Story | Follow @JustinHFierce

> MS docs, activists pressure U.K. cost watchdog to bless Biogen, GW meds. More

> Japanese companies follow Sanofi's lead in shunning Big Pharma M&A trend. Report

> Shaky Dendreon loses its CEO as debt payments loom. News

Pharma Manufacturing News

> FDA says compounder making drugs under unsanitary conditions. More

> Drugmaker will use MIT 3-D printing process to make fast-melting capsules. Item

> More consolidation in the API market as Provence picks up peptidemaker Synprosis. Report

> Illinois man pleads guilty to selling $3M worth of foreign Botox. Story

> Roche's Avastin and MabThera are added to list of those stolen in Italy. Article

> Dr. Reddy's avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production. More

Biotech Research News

> Compound could delay onset of Type 2 diabetes. Story

> ImStem therapy reverses multiple sclerosis symptoms in mice. More

> Levels of small molecule in brain may indicate depression. Article

> Report: $4.5B needed for BRAIN project through 2025. Item

> Stem cells transplanted successfully in pigs. Story

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.